These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127 [TBL] [Abstract][Full Text] [Related]
3. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082 [TBL] [Abstract][Full Text] [Related]
4. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors. Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030 [TBL] [Abstract][Full Text] [Related]
5. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. Galatin PS; Abraham DJ J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988 [TBL] [Abstract][Full Text] [Related]
8. Structure-based design of potent non-peptide MDM2 inhibitors. Ding K; Lu Y; Nikolovska-Coleska Z; Qiu S; Ding Y; Gao W; Stuckey J; Krajewski K; Roller PP; Tomita Y; Parrish DA; Deschamps JR; Wang S J Am Chem Soc; 2005 Jul; 127(29):10130-1. PubMed ID: 16028899 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of the interaction between MDM2 and p53. Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304 [TBL] [Abstract][Full Text] [Related]
10. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. Riedinger C; Endicott JA; Kemp SJ; Smyth LA; Watson A; Valeur E; Golding BT; Griffin RJ; Hardcastle IR; Noble ME; McDonnell JM J Am Chem Soc; 2008 Nov; 130(47):16038-44. PubMed ID: 18959403 [TBL] [Abstract][Full Text] [Related]
11. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex. Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742 [TBL] [Abstract][Full Text] [Related]
13. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Fasan R; Dias RL; Moehle K; Zerbe O; Vrijbloed JW; Obrecht D; Robinson JA Angew Chem Int Ed Engl; 2004 Apr; 43(16):2109-12. PubMed ID: 15083458 [No Abstract] [Full Text] [Related]
14. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Wang H; Nan L; Yu D; Agrawal S; Zhang R Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884 [TBL] [Abstract][Full Text] [Related]
15. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Popowicz GM; Czarna A; Holak TA Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113 [TBL] [Abstract][Full Text] [Related]
16. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. O'Hagan HM; Ljungman M Oncogene; 2004 Jul; 23(32):5505-12. PubMed ID: 15094782 [TBL] [Abstract][Full Text] [Related]
18. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. García-Echeverría C; Chène P; Blommers MJ; Furet P J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738 [No Abstract] [Full Text] [Related]
19. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction. Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630 [TBL] [Abstract][Full Text] [Related]
20. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors. Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]